LATEST
Corruption Files
Medical equipment warehouse
Medical Fraud

Texas Medical Equipment Owner Sentenced for $59 Million Medicare Scam

By

Raymond Lee, 51, owner of Houston-based DME Express, was sentenced Friday to 12 years in federal prison for orchestrating a $59 million Medicare fraud scheme involving unnecessary durable medical equipment (DME) and illegal kickbacks.

Lee paid $1,500 to $3,000 per month to telemedicine companies in exchange for pre-signed orders for power wheelchairs, hospital beds, and other DME — regardless of medical necessity. He then billed Medicare for the equipment, often at inflated rates. Prosecutors said Lee personally profited by at least $18 million between 2019 and 2024.

The scheme was uncovered after a Medicare audit revealed that Lee's company had the highest per-patient DME billing rate in Texas, despite having no physical therapy staff to assess patient needs.

Wider investigation ongoing

Lee was also ordered to pay $59 million in restitution and forfeit $18 million in assets, including a ranch, multiple luxury vehicles, and cryptocurrency accounts. Two telemedicine doctors who signed fraudulent orders have pleaded guilty and are cooperating with prosecutors.

'Raymond Lee treated Medicare like his personal ATM,' said U.S. Attorney Alamdar Hamdani. 'He will now have more than a decade to think about the patients who were denied care because of his greed.'

Raymond Lee treated Medicare like his personal ATM. He will now have more than a decade to think about the patients who were denied care because of his greed.

— U.S. Attorney Alamdar Hamdani

Lee's wife, who managed the company's finances, pleaded guilty to conspiracy and is scheduled for sentencing in May.

Mirror Standard — Investigative Journalism
Ruth Anselmi — author photo
About Author

Ruth trained as a pharmacist and then spent a decade watching the gap between clinical trial data and real-world outcomes grow wider every year. She left the industry after a whistleblower case she had quietly supported was settled out of court under a non-disclosure agreement. Her reporting cuts through press releases and FDA approval language to ask the questions that should have been asked before the drug reached the shelf.

SubstackMedium

Related posts